

# H&I UK NEQAS NHSBT OTDT H&I Incidents and Updates

– 11<sup>th</sup> May 2026

*Dr Carla Rosser*

*NHSBT OTDT H&I Lead*

# Topics

- OTDT Patient Safety team
- Reported NHSBT-OTDT Patient Safety incidents.
- H&I OTDT resources and how to access them.
- Scientific Support team update.
- NTxD Downtime.
- Ongoing activities.
- Contact information.

## What is an OTDT Clinical Incident?

- **Any event in the organ donation and/or transplantation process which can or does affect the donor, recipient, safety or the quality of the organs or tissue for transplantation**
- May have national or wider learning – reporting these provides an opportunity to strengthen our processes!
- NHSBT also hold an assisted function with the Human Tissue Authority - Legal requirement to report under HTA regulations – ODT Patient Safety/ODTQA will do this.

# OTDT Patient Safety Team



Blood and Transplant

A team of experienced healthcare professionals with specialist training to undertake a proportionate systems approach to patient safety events across the Organ and Tissue Donation and Transplant (OTDT) Pathway.


Email any queries to: [patientsafety.otdt@nhsbt.nhs.uk](mailto:patientsafety.otdt@nhsbt.nhs.uk)

Report any incidents via the online form, accessible internally via NHSBT Link or externally via ODT website:


<https://www.odt.nhs.uk/odt-structures-and-standards/clinical-governance-and-patient-safety/tell-us-about-an-incident/>

**Tell us about an incident**

Tell us about an incident by completing this [online form](#)

**INCIDENT SUBMISSION FORM** 

**Is incident deemed urgent and requires immediate action?**  No  Yes, not notified by phone  Yes, already notified by phone  
You will be unable to complete the rest of this form until you answer the question above.


- Fields marked with \* are mandatory, all other fields can be completed, if relevant, to provide information about the incident. For help completing fields, click on 
- To avoid losing data, please be aware this form will time out after **30 minutes** of inactivity and must be completed and submitted at the same time; it is not possible to partially complete the form and return to it later.
- In order to complete the form, please ensure that you have the relevant details and patient reference numbers to hand.

**Caring Expert Quality**

# OTDT 2025-2026 Patient Safety Incidents



## Blood and Transplant



- The error categories are for the purposes of this talk (i.e. not official)
- Between April 2025 to March 2026 there have been **50 H&I incidents** reported (compared to 29 for May 2024 to April 2025).
- This increase may be due to more clinical incidents being recorded rather than an increase in incidents.

# OTDT 2025-2026 Patient Safety Incidents – Detail (page 1)

Category Heading	Detail
Crossmatch material issue	Spleen pot unlabelled
	Spleen pot unlabelled and insufficient lymph node
	Unable to separate viable cells, or extract DNA, from spleen samples.
	Spleen pots damaged
	Spleen pot unlabelled
	No viable cells
	Smashed spleen pots
	Insufficient spleen and lymph node received
	Incorrect Information (Hub to H&I)
Incorrect donor HLA information sent to H&I	
Incorrect donor HLA information sent to H&I	
Incorrect ODT number on the HLA offer typing report (FRM4365)	
Incorrect donor HLA and matching run information sent to H&I	
Incorrect donor HLA information sent to H&I	
Failure of process (NHSBT)	SNOD chased HLA prior to donor being registered
	Patient had an incorrect HLA-DRB4* type on NTxD. Should have been flagged by automated checks. Did not affect allocation.
	Revised HLA type submitted via FRM4365 (minor change) but not sent to the recipient laboratories. Donation stood down.
	HLA report sent to H&I labs without ODT number on FRM4365.
	Laboratory not receiving the automated email reports.
	HLA type entered incorrectly by Hub as DPB1*01:01 homozygous. Corrected prior to retrieval.
Sample communication failure (SNOD to H&I)	Oncall staff not informed that samples should be processed.
	Oncall staff not informed that samples should be processed.
	Oncall staff not informed about samples
	SNOD unable to contact Tissue Typist for several hours.

# OTDT 2025-2026 Patient Safety Incidents – Detail (Page 2)

Category Heading	Detail
Incorrect PID provided	DCERT transfer failure due to PID
	Inconsistent information for patient name (middle) led to failure of two DCERT report submissions.
	Incorrect interpretation of potential deceased donor name from a hand-written request form.
	SNOD included nickname in brackets in the NTxD record led to DCERT failure.
DCERT technical	Duplicate DCERT report sent leading to error with NTxD requiring intervention by IT
	DCERT PDF did not attach. FRM4365 required.
	DCERT file took ~1 hour to reach OTDT. FRM4365 required
Laboratory process failure - data	Incorrect laboratory analyzer report attached to DCERT. Incorrect record retained in TransplantPath
	Incorrect laboratory report attached to FRM4936.
	DRB3/4/5 heterozygous allele reporting issue - systemic due to SureTyper output.
Laboratory process failure - DPB1	HLA-DPB1* could not be reported due to multiple rare alleles.
	Technical failure for HLA-DP only
Laboratory process failure - offer type	Incorrect offer type. HLA-C misreported. Resolved pre-allocation
	Incorrect offer type. Reported as DQ7, DQ8 rather than DQ7, X. Two recipients missed an offer.
Laboratory process failure - other	Suspension of deceased donor HLA typing service due to low staffing levels.
	Positive virtual crossmatch when a laboratory crossmatch was pending and subsequently negative. Lead to inappropriate decline of the organ.
NTxD Limitation	Collapsed UKLKSS chain due to allelic antibodies against HLA-DRB1*15:01. Can only list HLA-DR15 as an unacceptable, which excludes some compatible donors.
Transport	Delay in testing due to incorrect delivery location for samples.
	Delay in testing due to incorrect delivery location for samples.
	Delay in testing due to incorrect delivery location for samples.

# Offer type errors

HLA-C	<b>Cw1</b>		<b>*01</b>	<b>Cw3</b>	<b>Cw9</b>	<b>*03:03/XX</b>
-------	------------	--	------------	------------	------------	------------------

HLA-C	C*01	C*03	Cw1, -, Null; Cw9(w3), -, Null, Cw3	✓	(0)
-------	------	------	-------------------------------------	---	-----

## Allele results

Group	Allele	tolerance range: (1)	Serological eq.
C*01	C*01:02:44, 01:03:01-01:03:03, 01:05, 01:07:01, 01:07:02, 01:24, 01:36:01, 01:36:02, 01:49:01-01:50, 01:78-01:79:02, 01:90, 01:101-01:103, 01:113, 01:115, 01:116, 01:131, 01:136, 01:167, 01:248		Cw1, -
	C*01:145:01N, 01:145:02N, 01:224N, 01:231N		Null
C*03	C*03:03:01:01, 03:03:01:02-03:03:01:38, 03:03:01:39Q-03:03:01:49, 03:03:01:51, 03:03:01:53, 03:03:01:54, 03:03:01:55Q-03:03:03, 03:03:04, 03:03:05-03:03:20, 03:03:22-03:03:50, 03:03:52-03:03:63, 03:03:65-03:03:71, 03:11:01, 03:11:02, 03:13:01:01-03:13:02, 03:18:02, 03:18:03, 03:21, 03:22Q, 03:30, 03:43:02, 03:49, 03:50, 03:52, 03:53, 03:55, 03:56, 03:58, 03:59, 03:61, 03:62, 03:66, 03:68, 03:75, 03:76, 03:79, 03:81, 03:82, 03:85, 03:88, 03:06:01, 03:07		Cw9(w3), -, Cw3

# Offer type errors

HLA-C	<b>Cw3</b>	<b>Cw9</b>	<b>*03:03/XX</b>			
-------	------------	------------	------------------	--	--	--

HLA-B	B*15	B*27:05:02:01	B62(15); B27
HLA-C	C*03:03		Cw9(w3)

**Allele combinations**

Group	Allele	tolerance range: (0)	Serological eq.
C*03	C*03:03:01:01	03:03:01:02-03:03:01:38, 03:03:01:39Q-03:03:01:49, 03:03:01:51, 03:03:01:53, 03:03:01:54, 03:03:01:55Q-03:03:03, 03:03:04, 03:03:05-03:03:14, 03:03:16-03:03:20, 03:03:22-03:03:31, 03:03:33-03:03:41, 03:03:43-03:03:48, 03:03:50, 03:03:52-03:03:54, 03:03:56-03:03:63, 03:03:65-03:03:71, 03:11:01, 03:11:02, 03:18:02, 03:18:03, 03:22Q, 03:30, 03:50, 03:52, 03:53, 03:56, 03:59, 03:61, 03:62, 03:66, 03:68, 03:75, 03:76, 03:79, 03:81, 03:83, 03:85, 03:88, 03:96:01, 03:96:02, 03:103, 03:112, 03:116:01, 03:116:02, 03:120, 03:122, 03:124, 03:126, 03:127, 03:133, 03:141, 03:150, 03:152, 03:158, 03:160, 03:165:01, 03:165:02, 03:168, 03:171, 03:176, 03:185, 03:187, 03:188, 03:192, 03:195, 03:196, 03:202-03:207, 03:214, 03:217, 03:223, 03:227, 03:230, 03:237, 03:241-03:243, 03:253, 03:254, 03:262, 03:273, 03:275, 03:276, 03:284, 03:285, 03:288, 03:290, 03:291, 03:295, 03:304, 03:308, 03:312, 03:319-03:321, 03:324, 03:325, 03:327, 03:336, 03:339, 03:341, 03:345, 03:351, 03:352, 03:356, 03:357, 03:360, 03:364, 03:367, 03:370, 03:372:01, 03:372:02, 03:374, 03:375, 03:378, 03:383, 03:389, 03:395, 03:398, 03:414, 03:416, 03:418, 03:422, 03:427, 03:428, 03:430, 03:433, 03:436, 03:438, 03:440, 03:451, 03:457, 03:460, 03:471, 03:472, 03:476, 03:477, 03:479, 03:481, 03:490, 03:495:01, 03:495:02, 03:503, 03:506, 03:507, 03:515-03:517, 03:519, 03:520, 03:524, 03:527-03:529, 03:533, 03:534, 03:537, 03:541, 03:545, 03:550, 03:551, 03:556, 03:563, 03:567, 03:568, 03:573, 03:574, 03:578, 03:579, 03:582, 03:583, 03:585, 03:586Q, 03:587, 03:592, 03:594, 03:595, 03:597, 03:598, 03:601, 03:606, 03:611, 03:616, 03:617, 03:622, 03:624, 03:632, 03:634, 03:639, 03:640, 03:651, 03:661, 03:665, 03:667, 03:670, 03:674, 03:679, 03:685, 03:688, 03:690, 03:691, 03:693, 03:694	Cw9(w3), -, Cw3
	C*03:03:01:50N, 03:03:01:52N, 03:20N, 03:189N, 03:229N, 03:363N, 03:377N, 03:380N, 03:421N, 03:432N, 03:444N, 03:447N, 03:509N, 03:560N, 03:628N, 03:635N, 03:636N		Null
C*03	C*03:03:01:01	03:03:01:02-03:03:01:38, 03:03:01:39Q-03:03:01:49, 03:03:01:51, 03:03:01:53, 03:03:01:54, 03:03:01:55Q-03:03:03, 03:03:04, 03:03:05-03:03:20, 03:03:22-03:03:63, 03:03:65-03:03:71, 03:04:01:36, 03:04:102, 03:04:110-03:04:112, 03:11:01, 03:11:02, 03:13:01-01:03:13:02, 03:18:02, 03:18:03, 03:21, 03:22Q, 03:30, 03:43:02, 03:49, 03:50, 03:52, 03:53, 03:55, 03:56, 03:58, 03:59, 03:61, 03:62, 03:66, 03:68, 03:73, 03:75, 03:76, 03:79, 03:81, 03:83, 03:85, 03:88, 03:96:01-03:97, 03:103, 03:112, 03:116:01, 03:116:02, 03:119:01, 03:120, 03:122, 03:124, 03:126, 03:127, 03:133, 03:139:02, 03:141, 03:144, 03:150-03:152, 03:158, 03:160, 03:161, 03:165:01, 03:165:02, 03:168, 03:171, 03:176, 03:177, 03:182, 03:185, 03:187, 03:188, 03:192, 03:195, 03:196, 03:202-03:207, 03:214, 03:217, 03:220, 03:223, 03:227, 03:228, 03:230, 03:237, 03:241-03:243, 03:253, 03:254, 03:262, 03:272, 03:273, 03:275, 03:276, 03:284, 03:285, 03:288-03:291, 03:295, 03:304, 03:308, 03:312, 03:319-03:321, 03:324, 03:325, 03:327, 03:336, 03:339, 03:341, 03:345, 03:351, 03:352, 03:356, 03:357, 03:360, 03:364, 03:367, 03:370, 03:372:01, 03:372:02, 03:374, 03:375, 03:378, 03:383, 03:389, 03:395, 03:398, 03:413, 03:414, 03:416, 03:418, 03:422, 03:427, 03:428, 03:430, 03:433, 03:436, 03:438, 03:440, 03:451, 03:457, 03:460, 03:471, 03:472, 03:474, 03:476, 03:477, 03:479, 03:481, 03:490, 03:495:01, 03:495:02, 03:503, 03:506, 03:507, 03:514-03:517, 03:519, 03:520, 03:524, 03:527-03:529, 03:533, 03:534, 03:537, 03:541, 03:545, 03:550, 03:551, 03:556, 03:563, 03:567, 03:568, 03:573, 03:574, 03:578, 03:579, 03:582, 03:583, 03:585, 03:586Q, 03:587, 03:590, 03:592, 03:594, 03:595, 03:597-03:599, 03:601, 03:606, 03:608, 03:609, 03:611, 03:616, 03:617, 03:620-03:622, 03:624, 03:627, 03:629, 03:632-03:634, 03:639, 03:640, 03:645, 03:649, 03:651, 03:652, 03:661, 03:665, 03:667, 03:670, 03:674, 03:679, 03:685-03:691, 03:693, 03:694	Cw9(w3), -, Cw10(w3), Cw3
	C*03:03:01:50N, 03:03:01:52N, 03:20N, 03:189N, 03:229N, 03:316N, 03:363N, 03:377N, 03:380N, 03:421N, 03:432N, 03:444N, 03:447N, 03:509N, 03:560N, 03:628N, 03:635N, 03:636N, 03:659N		Null

# Offer type errors

-DQB1	—	—	DQB1*03:01/xx	—	—	DQB1*03:02/xx
HLA-DRB1	DRB1*04 DRB1*04	DR4 DR4		HLA-DRB345	DRB4*01	DR53
HLA-DQA1	DQA1*03 DQA1*03	DQA03 DQA03		HLA-DQB1	DQB1*03 DQB1*03	DQ7 DQ7

GROUP	ALLELES	ANTIGEN
DQB1*03	DQB1* 03:01:01:01, 03:01:01:02e-03:01:02e, 03:01:03d-03:01:04:01d, 03:01:04:02e-03:01:61e	DQ7
	DQB1* 03:10:02e-03:10:03e	DQ8
	DQB1* 03:09, 03:13d, 03:16e, 03:19:01:01, 03:19:01:02Qe-03:19:06e, 03:21e-03:22:02e, 03:24e, 03:27e-03:29e, 03:35e-03:36e, 03:38:02e, 03:42e, 03:44e, 03:46e-03:60e, 03:69e, 03:71e, 03:73e, 03:75e-03:78e, 03:82e-03:84Ne, 03:92e-03:94e, 03:101e-03:103e, 03:108e-03:109e, 03:114e-03:116e, 03:118Ne-03:122e, 03:127e-03:131e, 03:133e-03:135e, 03:139e-03:140e, 03:142e-03:144e, 03:147e-03:148e, 03:150e-03:152e, 03:154e, 03:157e-03:160e, 03:162e-03:167e, 03:169e-03:173e, 03:182e-03:183e, 03:186e-03:188e, 03:191e-03:194e, 03:196e-03:198e, 03:201e-03:202e, 03:206e-03:207e, 03:216e, 03:218e-03:219e, 03:231e-03:232e, 03:235e-03:236e, 03:241e-03:243e, 03:246e, 03:252e-03:257e, 03:260e, 03:264e, 03:266e-03:268e, 03:271e, 03:275e-03:276Ne, 03:281e, 03:284e-03:286e, 03:288e, 03:290e-03:294e, 03:297e, 03:302e-03:303Ne, 03:305e-03:307e, 03:309e, 03:311e-03:312e, 03:314e, 03:317e, 03:326e, 03:328e-03:331e, 03:335e, 03:338Ne, 03:340Ne-03:342e, 03:347e, 03:350e, 03:353e-03:355e, 03:358Ne, 03:360e-03:361e, 03:366e, 03:370e, 03:372e-03:373e, 03:376Ne-03:378e, 03:380e-03:381e, 03:385Ne, 03:387e, 03:389e-03:391e, 03:394e, 03:396e, 03:400Ne-03:401e, 03:404e, 03:407Ne-03:408e, 03:417e-03:421e, 03:423e-03:428e, 03:430e-03:432e, 03:434e-03:436e, 03:438e-03:439e, 03:448e-03:449e, 03:451e, 03:454e-03:455e, 03:458e, 03:460e, 03:465e, 03:467e-03:470e, 03:472e-03:473Ne, 03:475e-03:476e, 03:480Qe, 03:482e-03:483e, 03:485e-03:486e, 03:488Ne, 03:491e-03:492e, 03:496e-03:497e, 03:499Ne, 03:503e, 03:506e, 03:508e, 03:513e-03:514e, 03:519e-03:520e, 03:522e, 03:524e, 03:526e-03:528e	-
DQB1*03	DQB1* 03:04:01:01, 03:04:01:02e-03:04:04e	DQ7
	DQB1* 03:02:02:01d, 03:02:02:02e, 03:02:05e-03:02:07e, 03:02:11e, 03:02:15e, 03:02:23e, 03:02:30e, 03:05:05e	DQ8
	DQB1* 03:14:01e, 03:45e, 03:63e, 03:67e-03:68e, 03:80e, 03:132e, 03:184e, 03:211e, 03:220e, 03:224e, 03:279e, 03:300e, 03:318e, 03:327e, 03:362e, 03:443e, 03:462e	-

# Offer type errors

-DQB1	—	—	DQB1*03:01/xx	—	—	DQB1*03:04/xx
-------	---	---	---------------	---	---	---------------

HLA-DRB1	DRB1*04 DRB1*04	DR4 DR4	HLA-DRB345	DRB4*01	DR53
HLA-DQA1	DQA1*03 DQA1*03	DQA03 DQA03	HLA-DQB1	DQB1*03 DQB1*03	DQ7 DQ7

GROUP	ALLELES	ANTIGEN
DQB1*03	DQB1* 03:01:01:01, 03:01:01:02e-03:01:02e, 03:01:03d-03:01:04:01d, 03:01:04:02e-03:01:61e	DQ7
	DQB1* 03:10:02e-03:10:03e	DQ8
	DQB1* 03:09, 03:13d, 03:16e, 03:19:01:01, 03:19:01:02Qe-03:19:06e, 03:21e-03:22:02e, 03:24e, 03:27e-03:29e, 03:35e-03:36e, 03:38:02e, 03:42e, 03:44e, 03:46e-03:60e, 03:69e, 03:71e, 03:73e, 03:75e-03:78e, 03:82e-03:84Ne, 03:92e-03:94e, 03:101e-03:103e, 03:108e-03:109e, 03:114e-03:116e, 03:118Ne-03:122e, 03:127e-03:131e, 03:133e-03:135e, 03:139e-03:140e, 03:142e-03:144e, 03:147e-03:148e, 03:150e-03:152e, 03:154e, 03:157e-03:160e, 03:162e-03:167e, 03:169e-03:173e, 03:182e-03:183e, 03:186e-03:188e, 03:191e-03:194e, 03:196e-03:198e, 03:201e-03:202e, 03:206e-03:207e, 03:216e, 03:218e-03:219e, 03:231e-03:232e, 03:235e-03:236e, 03:241e-03:243e, 03:246e, 03:252e-03:257e, 03:260e, 03:264e, 03:266e-03:268e, 03:271e, 03:275e-03:276Ne, 03:281e, 03:284e-03:286e, 03:288e, 03:290e-03:294e, 03:297e, 03:302e-03:303Ne, 03:305e-03:307e, 03:309e, 03:311e-03:312e, 03:314e, 03:317e, 03:326e, 03:328e-03:331e, 03:335e, 03:338Ne, 03:340Ne-03:342e, 03:347e, 03:350e, 03:353e-03:355e, 03:358Ne, 03:360e-03:361e, 03:366e, 03:370e, 03:372e-03:373e, 03:376Ne-03:378e, 03:380e-03:381e, 03:385Ne, 03:387e, 03:389e-03:391e, 03:394e, 03:396e, 03:400Ne-03:401e, 03:404e, 03:407Ne-03:408e, 03:417e-03:421e, 03:423e-03:428e, 03:430e-03:432e, 03:434e-03:436e, 03:438e-03:439e, 03:448e-03:449e, 03:451e, 03:454e-03:455e, 03:458e, 03:460e, 03:465e, 03:467e-03:470e, 03:472e-03:473Ne, 03:475e-03:476e, 03:480Qe, 03:482e-03:483e, 03:485e-03:486e, 03:488Ne, 03:491e-03:492e, 03:496e-03:497e, 03:499Ne, 03:503e, 03:506e, 03:508e, 03:513e-03:514e, 03:519e-03:520e, 03:522e, 03:524e, 03:526e-03:528e	-
DQB1*03	DQB1* 03:04:01:01, 03:04:01:02e-03:04:04e	DQ7
	DQB1* 03:02:02:01d, 03:02:02:02e, 03:02:05e-03:02:07e, 03:02:11e, 03:02:15e, 03:02:23e, 03:02:30e, 03:05:05e	DQ8
	DQB1* 03:14:01e, 03:45e, 03:63e, 03:67e-03:68e, 03:80e, 03:132e, 03:184e, 03:211e, 03:220e, 03:224e, 03:279e, 03:300e, 03:318e, 03:327e, 03:362e, 03:443e, 03:462e	-

# Offer type errors



Blood and Transplant

HLA Typing Discrepancies Pre and Post Allocation 2025

Laboratory (Origin of discrepancy)	No. of Offer types	No. of anomalies resolved prior to allocation	Anomalies Pre-Allocation %	No. Of Discrepancies resolved post allocation	Discrepancies Post-Allocation %	Discrepancies that had impact on allocation	Non-Compliance with minimum HLA typing resolutions for donors	Minimum typing resolution non compliance %
Barnsley	91							
Belfast	64							
Birmingham	138			1	0.72%	1		
Bristol	109							
Cambridge	180							
Cardiff	78						1	1.28%
Dublin	0							
Edinburgh	60							
Glasgow	59							
Guys	102							
WLRTC	71							
Leeds	91							
Leicester	49							
Liverpool	74							
Manchester	104							
Newcastle	110							
Oxford	64							
Plymouth	68						1	1.47%
Royal Free	24	1	4.10%					
Royal London	93							
Tooting	168							
ODT	1797							
<b>Total</b>	<b>1797</b>	<b>1</b>	<b>0.05%</b>	<b>1</b>	<b>0.05%</b>	<b>1</b>	<b>2</b>	<b>0.11%</b>

*\*Based on HLA re-typing information submitted to NHSBT-OTDT by recipient transplant centre laboratories*

Available to download from "Papers" at:  
<https://www.odt.nhs.uk/transplantation/pathology-services/histocompatibility-and-immunogenetics/>

**Caring Expert Quality**

# NTxD/LivingPath Recipient Registration Incidents



Blood and Transplant

## Detail

Unacceptable antigen listed as DPB402 in error instead of DPB0402 leading to an inappropriate offer.

Patient HLA type incorrectly entered as DQB1\*0301 (old nomenclature) rather than DQB1\*03:01 – no impact on matching.

Missing UAGs following reactivation on 25/06/2025 for pancreas alone.











An outdated UAG profile was used for re-transplant activation in UKLKSS. H&I laboratory unaware

Patient HLA type entered incorreced as B\*15:01 instead of B\*51:01




DP UAGs entered in molecular format (e.g. DPB1\*04:01 rather than DPB0401) leading to inapproriate offer.

## [Histocompatibility and Immunogenetics - ODT Clinical - NHS Blood and Transplant](#)

### Downloadable Resources about H&I

- [Bowel Transplantation Standardisation of testing reporting and crossmatch protocols in the UK \(PDF 23KB\)](#) 
- [HLA specific antibodies in CT Transplantation \(PDF 19KB\)](#) 
- [Guidance for entering HLA matchgrade when registering a patient \(PDF 17KB\)](#) 
- [HLA Antigen Frequencies in UK Solid Organ Donor Population \(PDF 8KB\)](#) 
- [FRM4365 HLA Report Form \(PDF 375KB\)](#) 
- [HLA conversion chart for organ allocation \(PDF 458KB\)](#) 
- [DAT2885 - Minimum resolution for reporting donor and recipient HLA types \(PDF 150KB\)](#) 
- [Donor blood sample requirements \(PDF 12KB\)](#) 
- [SOP5038/4 Reporting of Deceased Donor Types to NHSBT-ODT \(PDF 753KB\)](#) 
- [INF1713: Out of hours contact details for back-up HLA laboratories \(Excel 272KB\)](#)
- [INF1766/1 Unacceptable Antigen Mapping Chart \(PDF 106KB\)](#) 

### Papers

- [HLA typing discrepancies pre and post allocation 2022 \(PDF 428KB\)](#) 
- [HLA typing discrepancies pre and post allocation 2023 \(PDF 425KB\)](#) 
- [HLA typing discrepancies pre and post allocation 2024 \(PDF 428KB\)](#) 


- Many of these documents are out-of-date and need updating.
- However, they do capture some of the NTxD idiosyncrasies.
- If in doubt, contact Scientific Support for guidance via [ODTScientificInformationOfficers@nhsbt.nhs.uk](mailto:ODTScientificInformationOfficers@nhsbt.nhs.uk).

[Histocompatibility and Immunogenetics - ODT Clinical - NHS Blood and Transplant](#)

Version 09/ 2019

## NATIONAL TRANSPLANT DATABASE HLA CONVERSION CHART FOR ORGAN ALLOCATION

HLA Dictionary 2008 Nomenclature April 2010



## DAT2885/3.2 – Minimum Resolution for Donor and Patient HLA types



Blood and Transplant

Copy No:

Effective date: 09DEC2025

### MINIMUM RESOLUTION REPORTING REQUIREMENTS FOR DONOR AND PATIENT HLA TYPES

HLA-A, -B, -Cw, -DR, -DQB1 and –DPB1 information is required for all registration HLA types. Where broad and split information is not provided, allelic information must be provided to a resolution that enables the algorithm to infer a serological equivalent (e.g. HLA-DQB1\*03:01 rather than HLA-DQB1\*03). Supertypic specificities (i.e. HLA-Bw4/6, DR51/51N/52/53 and DR53N) may be reported but are not required.

HLA-A Broad	Splits (or associated specificities)
A1	
A2	
A3	
A9	A23, A24
A10	A25, A26, A34, A66
A11	
A19	A29, A30, A31, A32, A33, A74
A28	A68, A69
A36	
A43	
A80	

HLA-B Broad	Splits (or associated specificities)
B5	B51, B52
B7	
B8	
B12	B44, B45

HLA-Cw Broad	Splits (or associated specificities)
Cw1	
Cw2	
Cw3	Cw9, Cw10
Cw4	
Cw5	
Cw6	
Cw7	
Cw8	
Cw12	
Cw14	
Cw15	
Cw16	
Cw17	
Cw18	

HLA-DR Broad	Splits (or associated specificities)
DR1	

### Histocompatibility and Immunogenetics - ODT Clinical - NHS Blood and Transplant

#### INF1766/1 – Unacceptable Antigen Mapping Chart



Blood and Transplant  
Effective date: 12FEB2025

#### NATIONAL TRANSPLANT DATABASE UNACCEPTABLE ANTIGEN MAPPING CHART

Except where given, a recipient unacceptable antigen will only exclude that donor antigen

Recipient Unacceptable Antigen	Donor Antigen(s) Excluded	Recipient Unacceptable Antigen	Donor Antigen(s) Excluded
A2	A2 A203 A210	Cw3	Cw3 Cw9 Cw10
A9	A9 A23 A24 A2403		
A24	A24 A2403		
A10	A10 A25 A26 A34 A66		
A19	A19 A29 A30 A31 A32 A33 A74		
A28	A28 A68 A69		

\*The following antigens incorrectly eliminate their respective broad/split due to an NTxD Code Error.

Recipient Unacceptable Antigen*	Donor Antigen(s) Excluded*
A203	A2
A210	A2
A2403	A9 A24
B5102	B5 B51
B5103	B5 B51
B3902	B16 B39
B4005	B21
B2708	B27
DR1403	DR6 DR14
DR1404	DR6 DR14

Recipient Unacceptable Antigen	Donor Antigen(s) Excluded
DR2	DR2 DR15 DR16
DR3	DR3 DR17 DR18
DR5	DR5 DR11 DR12
DR6	DR6 DR13 DR14 DR1403 DR1404
DR14	DR14 DR1403 DR1404
DR51	DR2 DR15 DR16 DR51 <b>DR51Null*</b>
DR52	DR3 DR17 DR18 DR5 DR11 DR12 DR6 DR13 DR14 DR1403 DR1404 DR52
DR53	DR4 DR7 DR9 DR53 <b>DR53Null*</b>  Note: All DR7s will be excluded regardless of DR53/DR53Null status

# OTDT Scientific Support



Blood and Transplant

- Scientific Support can be contacted via:  
[ODTScientificInformationOfficers@nhsbt.nhs.uk](mailto:ODTScientificInformationOfficers@nhsbt.nhs.uk).
- This team check recipient and living donor registrations and may contact laboratories where a potential error is identified. Since late 2025, there has been support for these tasks from NHSBT H&I in this team with cover from H&I Scientists based in Barnsley, Birmingham, Filton and Newcastle via  
[ScientificSupportROTA@nhsbt.nhs.uk](mailto:ScientificSupportROTA@nhsbt.nhs.uk).
- **Mihaela Marfa** and **Megan Belshaw** will be joining this team full-time on 12-month secondment as Shakil Miah is being seconded to another NHSBT role.

- Communication is sent out to notify of planned OTDT systems down-time.
- However, there have been two unplanned NTxD downtime periods in 2026 – communication to external users was poor and we are seeking to improve this.
- During system down-time, OTDT Hub are unable to produce local matching runs and may initiate local offering if donation cannot wait until the system is back online (Hub Operations SOP4859). **This means that there needs to be a mechanism to identify a suitable donor locally at each transplant centre/laboratory.**

If no paper/PDF copy of the matching run is available:

The HOTM on shift will need to ensure that the OAS's on shift offer organs using the following guidance.

***Note:*** *If it has not been possible to enter the donor HLA onto NTxD, it will not be visible on TransplantPath. A copy of the HLA may be sent via NHS or NHSBT email to centres considering an offer.*

<https://www.odt.nhs.uk/deceased-donation/best-practice-guidance/procedural-documents/>

# Ongoing NHSBT-OTDT activities



Blood and Transplant

- National DCERT implementation is progressing with 9/20 laboratories now live – remainder by Autumn 2026.
- The matchability score = 10, 0% cRF issue was raised early 2025. This is being addressed via the NHSBT-KAG group, with modelling currently being undertaken.
- The cRF calculator (DPB1) updates are still pending – awaiting capacity in the Stats team to develop.
- Updates for H&I OTDT documentation are in progress.
- Continuing to raise awareness internally of the challenges of NTxD and ODT Online for H&I laboratories and HLA data. Hoping to get funding to update and implement ISOU recommendations – but this will take time!

# Contact Information



Blood and Transplant

Regular updates are available via the new OTDT H&I newsletter sent from the generic email address ([OTDTHandlsupportrequests@nhsbt.nhs.uk](mailto:OTDTHandlsupportrequests@nhsbt.nhs.uk)) – please email if you wish to receive this.

The generic email address is accessed by several individuals at NHSBT:

[OTDTHandlsupportrequests@nhsbt.nhs.uk](mailto:OTDTHandlsupportrequests@nhsbt.nhs.uk)

You can also contact me directly via:

[carla.rosser@nhsbt.nhs.uk](mailto:carla.rosser@nhsbt.nhs.uk)

Thank you!

Any further thoughts or questions?

Please email me: [carla.rosser@nhsbt.nhs.uk](mailto:carla.rosser@nhsbt.nhs.uk) or  
[OTDTHandlsupportrequests@nhsbt.nhs.uk](mailto:OTDTHandlsupportrequests@nhsbt.nhs.uk)